| Home | E-Submission | Sitemap | Editorial Office
Korean J Urol Oncol > Volume 15(3); 2017 > Article
Han, Choi, Yoo, Baek, Ryu, Kyung, Nam, Lee, You, Jeong, Hong, Ahn, and Kim: Impact of Histologic Variants of Bladder Cancer on Oncology Outcome After Radical Cystectomy



To evaluate the oncological outcome of histologic variants in bladder cancer patients who underwent radical cystectomy.

Materials and Methods

We identified 393 bladder cancer patients who underwent radical cystectomy at single center between January 2007 and August 2014. Patients were divided into 4 groups according to histologic types: pure urothelial cell carcinoma (UC) and squamous, micropapillary, and other variants. Kaplan-Meier analysis was performed to assess recurrence-free (RFS) and overall survivals (OS). The patients were divided into those with pathologic stage and nodal status.


Among 393 bladder cancer patients, squamous, micropapillary histologic variants were observed in 38 (9.7%), 26 (6.6%), respectively, whereas 39 had other variant types. Stage T3 cancer occurred in more patients with histologic variant compared with those with pure UC. Pathologic positive nodal status was also frequently found in the histologic variant groups. Subgroup analysis according to T stage and nodal status showed no significant difference in RFS and OS. On multivariate analysis, pathologic T stage (stage T2: hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.34–5.63; p=0.005; stage ≥ T3: HR, 3.20; 95% CI, 1.62–6.30; p=0.001) and nodal status (HR, 1.85; 95% CI, 1.05–2.56; p=0.028) were prognostic factors for RFS.


In patients who underwent radical cystectomy, histologic variants were detected more often at advanced pathologic stage. Although histologic variants have been identified in the radical cystectomy specimen, treatment should be performed according to the pathologic stage.


Bladder cancer is the sixth most common cancer in the United States, with more than 430,000 cases diagnosed worldwide.1 Morbidity and mortality are high, especially in the case of muscle invasion. Multimodal treatment with radical cystectomy and neoadjuvant chemotherapy is preferred.2 Urothelial cell carcinoma (UC) is the most common pathologic type, accounting for 90% of all bladder cancers.3 The 2004 World Health Organization (WHO) classification of UC listed 13 histologic variants.4,5 Several reports have noted the oncologic effect of histologic variants, although they vary from institution to institution. Interest in histologic variants has increased considering the various clinicopathological features of bladder cancer.
Some reports have noted that histologic variants affect oncologic outcome,6,7 whereas others have stated that the inclusion of variants in pathological analysis did not impact survival, and discrepancy regarding this still exists to date.810 Therefore, we aimed to determine the prognostic significance of histologic variants associated with recurrence and progression after radical cystectomy in a single-center cohort of patients with bladder cancer.


1. Study Design and Patients

In total, 424 patients underwent radical cystectomy between January 2007 and August 2014 at Asan Medical Center. Since 2007, histologic variants have been described according to the WHO classification. Our study included patients with UC bladder cancer who underwent radical cystectomy. We excluded 16 patients with adenocarcinoma, 1 with trauma, and 14 with other malignancy, leaving 393 who were enrolled in this study (290 with pure UC without histologic variants and 103 with histologic variants). All patients underwent lymphadenectomy and urinary diversion. Four groups were compared (a pure UC group and groups with squamous, micropapillary, and other variants) according to the 2004 WHO histologic classification system in the order in which they appear frequently. Recurrence-free survival (RFS) and overall survival (OS) were analyzed according to pathologic T stage using the Kaplan-Meier analysis. The entire cohort was divided into patients with pathologic stage ≤ T2 or lower and ≥ T3 or higher. All pathologic reports of radical cystectomy were read by pathologists at our institute. In the surgical characteristics, surgical margins included positive urinary tract resection margins with positive soft tissue margins.

2. Statistical Analysis

Categorical variables are presented as frequencies and percentages and continuous variables as mean with standard deviation. The chi-square and analysis of variance tests were used to evaluate the categorical and continuous variables, respectively. All available variables were evaluated using univariate and multivariate Cox proportional hazards regression analysis to assess the association between histologic type and survival outcomes. The significance level was set at p<0.05. Survival rates were compared using Kaplan-Meier analysis with the log rank test. All statistical analyses were performed using IBM SPSS Statistics ver. 21.0 (IBM Co., Armonk, NY, USA).


Among 393 patients, 103 (26.2%) had bladder cancer with histologic variants: 38 (9.7%) had squamous, 26 (6.6%) had micropapillary, 13 (3.3%) had sarcomatoid, 5 (1.3%) had nested, 4 (1.0%) had plasmacytoid, 3 (0.8%) had glandular differentiation, 2 (0.3%) had giant cell variant, 1 (0.3%) had micro-cystic, 1 (0.2%) had lymphoepithelioma-like, and 1 (0.2%) had lymphoma-like and plasmacytoid variants. In addition, there were 9 patients (2.3%) in whom more than 2 variants were mixed. Table 1 presents the frequency of histologic variants of UC in radical cystectomy specimens based on the 2004 WHO classification system.
Table 1.
Frequency of histologic variants of urothelial carcinoma treated with radical cystectomy (2004 World Health Organization classification system)
Variable Number of patients (%)
Pure urothelial carcinoma 290 (73.8)
Urothelial carcinoma variant 103 (26.2)
 Squamous cell differentiation 38 (9.7)
 Micropapillary variant 26 (6.6)
 Sarcomatoid differentiation 13 (3.3)
 Nested variant 5 (1.3)
 Plasmacytoid differentiation 4 (1.0)
 Glandular differentiation 3 (0.8)
 Giant cell variant 2 (0.3)
 Microcystic variant 1 (0.3)
 Lymphoepithelioma-like variant 1 (0.3)
 Lymphoma-like and plamacytoid variants 1 (0.3)
 Multiple mixed variant differentiation 9 (2.3)
Table 2 presents the clinical and pathological characteristics of all patients (n=393). Patients were divided into 4 groups according to histologic types: pure UC and squamous, micropapillary and other variants. Squamous variant group had the highest mean age (67 years) among the 4 groups. Clinical staging at transurethral resection of the bladder tumor (TURBT) showed the squamous variant group (94.1%) to have a higher percentage of muscle invasion (pure UC, 65.1%; micropapillary variant, 65.3%; other variants, 66.7%; p=0.003). Pathologic T stage also showed a significant difference. Compared with the pure UC group, variant groups demonstrated more extravesical stage disease (pure UC, 43.7%; squamous variant, 73.7%; micropapillary variant, 73.1%; other variants, 64.1%; p<0.001), a higher number of pathologically positive nodes (22.8%, 36.8%, 61.5%, and 35.9%, respectively; p<0.001), and more frequent lymphovascular invasion (LVI) (40.7%, 57.9%, 88.5%, and 59%, respectively; p<0.001).
Table 2.
Clinicopathological characteristics of all patients
Characteristic Pure UC Squamous variant Micropapillary variant Other variants p-value
No. of patients (%) 290 (73.8) 38 (9.7) 26 (6.6) 39 (9.9)  
Age (yr) 63.3±9.7 67.0±8.9 62.0±12.2 59.3±12.3 0.009
Sex         0.531
 Male 249 (85.8) 33 (86.8) 24 (92.4) 31 (79.5)  
 Female 41 (14.2) 5 (13.2) 2 (7.6) 8 (20.5)  
Body mass index (kg/m2) 24.2±3.0 23.6±2.5 23.3±2.8 24.0±3.5 0.343
TURBT stage         0.003
 Nonmuscle invasive 101 (34.9) 2 (5.3) 9 (34.7) 13 (33.3)  
 Muscle invasive 189 (65.1) 36 (94.7) 17 (65.3) 26 (66.7)  
Pathologic T stage         < 0.001
 ≤T1 107 (36.8) 1 (2.6) 2 (7.6) 3 (7.6)  
 T2 56 (19.3) 9 (23.7) 5 (19.3) 11 (28.3)  
 ≥T3 127 (43.7) 28 (73.7) 19 (73.1) 25 (64.1)  
Pathologic nodal status         < 0.001
 Node negative 224 (77.2) 24 (63.2) 10 (38.5) 25 (64.1)  
 Node positive 66 (22.8) 14 (36.8) 16 (61.5) 14 (35.9)  
Surgical margin status         0.240
 Margin negative 261 (90.0) 36 (94.7) 21 (80.8) 33 (84.6)  
 Margin positive 29 (10.0) 2 (5.3) 5 (19.2) 6 (15.4)  
Pathologic grade         0.203
 Low grade 16 (5.5) 1 (2.6) 0 (0) 1 (2.6)  
 High grade 254 (87.6) 37 (97.4) 26 (100) 37 (94.8)  
 Unknown 20 (6.9) 0 (0) 0 (0) 1 (2.6)  
CIS         0.131
 Absent 179 (61.7) 26 (68.4) 12 (46.2) 19 (48.7)  
 Present 111 (38.3) 12 (31.6) 14 (53.8) 20 (51.3)  
LVI         < 0.001
 Absent 172 (59.3) 16 (42.1) 3 (11.5) 16 (41.0)  
 Present 118 (40.7) 22 (57.9) 23 (88.5) 23 (59.0)  
Neoadjuvant chemotherapy 27 (9.3) 8 (21.1) 1 (3.8) 8 (20.5) 0.023
Adjuvant chemotherapy 80 (27.6) 14 (36.8) 13 (50.0) 15 (38.5) 0.055

Values are presented as number (%) or mean±standard deviation.

UC: urothelial carcinoma, TURBT: transurethral resection of bladder tumor, CIS: carcinoma in situ, LVI: lymphovascular invasion.

Among the study patients, 109 (27.7%) died during a median follow-up of 28 months (interquartile range [IQR], 12–56 months) and 108 (27.5%) had recurrence postoperatively (median follow-up until local recurrence or distant metastasis, 28 months; IQR, 12–56 months). The 5-year RFS rates were 71.2% and 51.3%, 44.2%, and 34.0% for the pure UC and squamous, micropapillary, and other variant groups, respectively. The 5-year OS rates were 87.8% and 42.8%, 44.0%, and 51.4%, respectively. The RFS and OS rates for the pure UC group were statistically superior to those of the squamous (p=0.049 and p=0.005, respectively) and other (p=0.005 and p=0.031, respectively) variant groups (Fig. 1A, B).
Fig. 1.
Recurrence-free survival and overall survival comparisons of histologic variants (entire cohort). TCC: transitional cell carcinoma, SQV: squamous variant, MPV: micropapillary variant.
Figs. 2 and 3 show the Kaplan-Meier survival analysis of RFS and OS, dividing the entire cohort into patients with pathologic stage ≤ T2 and ≥ T3 cancer. Patients with pure UC had a better RFS rate than those in the other variants group (p=0.009), but there was no significant difference in OS between each group (Fig. 2). Patients with pathologic stage T3 disease demonstrated no significant difference in RFS and OS rates (Fig. 3).
Fig. 2.
Recurrence-free survival and overall survival comparison of histologic variants (≤ pT2). TCC: transitional cell carcinoma, SQV: squamous variant, MPV: micropapillary variant.
Fig. 3.
Recurrence-free survival and overall survival comparison of histologic variants (≥ pT3). TCC: transitional cell carcinoma, SQV: squamous variant, MPV: micropapillary variant.
Figs. 4 and 5 show the Kaplan-Meier survival analysis of RFS and OS dividing into node positive and node negative pathology. There was no significant difference in survival between the pure UC group and the variant groups, but only the other variants group showed significantly lower survival result in node negative patients analysis on RFS (p=0.008).
Fig. 4.
Recurrence-free survival and overall survival comparison of histologic variant (node negative). TCC: transitional cell carcinoma, SQV: squamous variant, MPV: micropapillary variant.
Fig. 5.
Recurrence-free survival and overall survival comparison of histologic variant (node positive). TCC: transitional cell carcinoma, SQV: squamous variant, MPV: micropapillary variant.
Univariate analysis demonstrated pathologic T stage, nodal status, surgical margin status, body mass index (BMI), LVI, and histologic variant (squamous variant and other variant) to be factors affecting RFS (Table 3). However, on multivariate analysis, significant predictors of RFS were pathologic T stage (stage T2: hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.34–5.63; p=0.005; stage≥ T3: HR, 3.20; 95% CI, 1.62– 6.30; p=0.001) and nodal status (HR, 1.64; 95% CI, 1.05–2.56; p=0.028). Histologic types (squamous and other variants) were a significant factor for RFS on univariate analysis, but not on multivariate analysis adjusted by T and N stage.
Table 3.
Univariate and multivariate Cox regression analysis for predicting RFS
Variable Univariate analysis Multivariate analysis
Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Age (yr) 1.00 (0.98–1.02) 0.785    
 Male Reference      
 Female 1.49 (0.91–2.43) 0.105    
Body mass index (kg/m2) 0.93 (0.87–0.99) 0.026 0.95 (0.90–1.01) 0.173
Pathologic T stage
Nonmuscle invasive (pT0/Ta/T1/CIS) Reference      
 Muscle invasive (T2) 3.41 (1.71–6.80) < 0.001 2.75 (1.34–5.63) 0.005
 Extravesical (T3/T4) 4.79 (2.59–8.86) < 0.001 3.20 (1.62–6.30) 0.001
Histologic grade
 Low Reference      
 High 2.09 (0.66–6.61) 0.206    
 pT0 or not remarked 0.50 (0.08–3.02) 0.455    
Surgical margin status
 Negative Reference      
 Positive 1.92 (1.15–3.19) 0.011 1.37 (0.80–2.34) 0.244
 Absent Reference      
 Present 1.16 (0.79–1.71) 0.439    
 Absent Reference      
 Present 2.32 (1.57–3.43) < 0.001 1.24 (0.78–1.98) 0.353
Pathologic nodal status
 Node negative Reference      
 Node positive 2.43 (1.65–3.57) < 0.001 1.64 (1.05–2.56) 0.028
Histologic type
 Pure UC Reference      
 Squamous variant 1.84 (1.00–3.41) 0.05 1.26 (0.67–2.36) 0.467
 Micropapillary variant 1.23 (0.56–2.67) 0.60 0.64 (0.28–1.42) 0.277
 Other variants 2.10 (1.13–3.87) 0.01 1.53 (0.82–2.85) 0.175

RFS: recurrence-free survival, HR: hazard ratio, CI: confidence interval, CIS: carcinoma in situ, LVI: lymphovascular invasion; UC: urothelial carcinoma.

Table 4 presents risk factors affecting OS of the entire cohort. Pathologic T stage (stage≥ T3: HR, 3.68; 95% CI, 1.89–7.15; p<0.001), nodal status (HR, 2.01; 95% CI, 1.30–3.10; p=0.002) and BMI (HR, 0.92; 95% CI, 0.87–0.98; p=0.021) were significant predictors of OS. Although the squamous variant group showed statistical difference on univariate analysis (HR, 2.20; 95% CI, 1.25–3.84; p=0.006), no difference was noted on multivariate analysis (HR, 1.59; 95% CI, 0.89–2.83; p=0.114) for predicting OS.
Table 4.
Univariate and multivariate Cox regression analysis for predicting OS
Variable Univariate analysis Multivariate analysis
Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Age (yr) 1.01 (0.99–1.03) 0.171    
 Male Reference      
 Female 1.22 (0.73–2.05) 0.442    
Body mass index (kg/m2) 0.90 (0.84–0.95) 0.001 0.92 (0.87–0.98) 0.021
Pathologic T stage
 Nonmuscle invasive (pT0/Ta/T1/CIS) Reference      
 Muscle invasive (T2) 2.06 (0.94–4.49) 0.068 1.60 (0.72–3.55) 0.242
 Extravesical (T3/T4) 5.53 (2.95–10.39) < 0.001 3.68 (1.89–7.15) < 0.001
Histologic grade
 Low Reference      
 High 1.17 (0.47–2.08) 0.728    
 pT0 or not remarked 0.48 (0.11–2.02) 0.319    
Surgical margin status
 Negative Reference      
 Positive 1.98 (1.22–3.22) 0.006 1.35 (0.81–2.25) 0.238
 Absent Reference      
 Present 1.05 (0.71–1.56) 0.775    
 Absent Reference      
 Present 2.83 (1.90–4.23) < 0.001 1.34 (0.83–2.17) 0.228
Pathologic nodal status
 Node negative Reference      
 Node positive 2.60 (1.54–4.38) < 0.001 2.01 (1.30–3.10) 0.002
Histologic type
 Pure UC Reference      
 Squamous variant 2.20 (1.25–3.84) 0.006 1.59 (0.89–2.83) 0.114
 Micropapillary variant 1.54 (0.77–3.09) 0.218 0.72 (0.35–1.47) 0.370
 Other variants 1.82 (0.96–3.45) 0.063 1.15 (0.58–2.25) 0.684

OS: overall survival, HR: hazard ratio, CI: confidence interval, UC: urothelial carcinoma, CIS: carcinoma in situ, LVI: lymphovascular invasion.


We aimed to identify the oncological outcome of UC, including histologic variants, in comparison with pure UC. Almost 25%–30% of patients with UC of the bladder show muscle invasion in the cystectomy specimen, for which radical cystectomy is the standard treatment.11,12 Muscle invasive bladder cancer carries a high risk of death because of disease progression, recurrence, and metastasis.13 Previous studies have reported approximately 10%–40% of bladder cancers show histologic variants on pathology results.14 Shah et al.7 reported that among 101 patients, the squamous variant was the most frequent, followed by glandular and micropapillary variants. In patients who underwent radical cystectomy, the squamous variant accounted for approximately 10%–22% of cancers.6,10 In our study, the squamous variant also was the most common (9.7%). The micropapillary variant has been reported in approximately 0.7%–6.0% of cases15,16 and occurred in 6.6% of our patients. Similar to other reports, nested, plasmacytoid differentiation, giant cell, microcystic, lymphoepithelioma-like, lymphoma-like, and plasmacytoid variants were rare in our study.
In several studies, histologic variants were reported to be the contributing factors of poor oncological outcome. One report indicated tumor size and squamous differentiation to be predictors of prognosis and cancer-specific survival.6 The micropapillary variant has been suggested to be a major factor associated with cancer-related mortality.10,16 The plasmacytoid variant also has been reported to be associated with mortality with the micropapillary variant.10 Also, histologic variants in lymph node positive urothelial bladder cancer have been reported to be a significant factor of worse outcome.17
In contrast, several studies have indicated that histologic variants were not factors influencing oncological outcome. In a prognostic analysis of squamous and glandular variants, there was no oncologic outcome difference between both variant groups.18 Indeed, one large study reported that the squamous variant itself did not affect the prognosis.3 Unlike other reports stating that the micropapillary variant acts as a poor prognostic factor, some studies report no difference compared with pure UC regarding surgical outcome when controlling for pathological factors.9 Moreover, in a recent study of 303 patients who underwent trimodal bladder-sparing therapy for muscle invasive bladder cancer, histologic variants of UC did not affect oncologic outcome.8 Our study also concluded that the effect of histologic variant on oncologic outcome in patients who underwent radical cystectomy was not different from that in patients with pure UC. The OS rate of patients with histologic variants in the cohort seemed to be lower than that of patients with pure UC because histologic variants were more commonly of advanced pathologic stage. Each histologic variant group showed no worse outcome than pure UC according to nodal status except for other variants group of nodal negative patients in RFS. In previous study, variant groups were considered to be factors affecting the survival rate on node positive patients.17 However, we found that there was no significant difference when the histologic variant types were identified in node positive group analysis.
Consequently, there was no significant difference in the survival rate of patients with variants when controlling for pathologic stage and nodal status, also these findings have been supported by several studies.6,9,18
Regarding treatment strategy, Krasnow et al.8 reported that patients with histologic variants found at TURBT should be advised of the adverse clinical course and cystectomy should be strongly recommended. In this study, we did not investigate the response to chemotherapy, but many studies reported a poor response with neoadjuvant chemotherapy.19,20 The amount of histologic variants or the mitotic rate has been reported to change significantly after neoadjuvant chemotherapy, and pathologic T stage has been downstaged after neoadjuvant chemotherapy, especially in the case of the squamous variant. The advantage of this study was that we analyzed the recurrence and survival rates according to the pathophysiological characteristics of the histologic variants. According to the stage, histologic variants were identified more often at an advanced stage than pure UC. The reason for this may be because some variant cells exhibit more rapid growth characteristics or the diagnosis is delayed because of atypical symptoms.21,22
In our study BMI was a factor affecting OS (HR, 0.92; 95% CI, 0.87–0.98; p=0.021). One article noted that obesity is associated with an increased risk of bladder cancer.23,24 However, there was no report that obesity is related to the survival rate of bladder cancer. The effect of BMI on OS in our study may need to be confirmed in larger cohort studies.
Our study has several limitations. First, we might have an interobserver reliability problem in terms of variant quantity for interpretation of the same specimen during the study period. Second, survival analysis of pure UC and histologic variants might be affected because of the lack of analysis of the neoadjuvant chemotherapy effect. Third, we did not analyze the histologic variant in TURBT pathology specimens to predict variants in the cystectomy specimens. A few studies have reported the tendency for histologic variants to occur in TURBT and radical cystectomy specimens. In TURBT pathologic studies, 20%–50% of patients were reported to have a variant component.7,14 However, according to Abd El-Latif et al.,14 the sensitivity of initial biopsy or TURBT to detect variants in cystectomy specimens is as low as 39%. Finally, the number of patients in our study was low. Because the 2004 WHO bladder cancer classification has been used to describe the histologic variants from 2007 onwards, we were unable to investigate previous patients, so we were limited only to those studied afterwards.


In patients who underwent radical cystectomy, histologic variants were detected more often at a locally advanced stage. The outcome for patients with histologic variants appeared to be worse; however, they were more likely to have advanced clinical and pathological stage disease. So we concluded that though histologic variants have been identified in the radical cystectomy specimen, the treatment for the bladder cancer patients should be performed according to the pathologic stage.

Conflict of Interest

The authors claim no conflicts of interest.


1. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmströ m PU, Choi W, et al. Bladder cancer. Lancet 2016;388:2796–810
crossref pmid
2. Kukreja JB, Shah JB. Advances in surgical management of muscle invasive bladder cancer. Indian J Urol 2017;33:106–10
crossref pmid pmc
3. Gluck G, Hortopan M, Stă nculeanu D, Chiriță M, Stoica R, Sinescu I. Comparative study of conventional urothelial carcinoma, squamous differentiation carcinoma and pure squamous carcinoma in patients with invasive bladder tumors. J Med Life 2014;7:211–4
pmid pmc
4. Bertz S, Hartmann A, Knü chel-Clarke R, Gaisa NT. Specific types of bladder cancer. Pathologe 2016;37:40–51
crossref pmid pdf
5. Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J 2009;3((6 Suppl 4)):S193–8
crossref pmid pmc
6. Antunes AA, Nesrallah LJ, Dall'Oglio MF, Maluf CE, Camara C, Leite KR, et al. The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy. Int Braz J Urol 2007;33:339–45
crossref pmid pdf
7. Shah RB, Montgomery JS, Montie JE, Kunju LP. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol 2013;31:1650–5
crossref pmid
8. Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, et al. Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy. Eur Urol 2017;72:54–60
crossref pmid
9. Masson-Lecomte A, Colin P, Bozzini G, Nison L, de La Taille A, Comperat E, et al. Impact of micropapillary histological variant on survival after radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 2014;32:531–7
crossref pmid
10. Monn MF, Kaimakliotis HZ, Pedrosa JA, Cary KC, Bihrle R, Cheng L, et al. Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol Oncol 2015;33:18e15–18.e20
11. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666–75
crossref pmid
12. Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995;76:833–9
crossref pmid
13. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859–66
crossref pmid
14. Abd El-Latif A, Watts KE, Elson P, Fergany A, Hansel DE. The sensitivity of initial transurethral resection or biopsy of bladder tumor(s) for detecting bladder cancer variants on radical cystectomy. J Urol 2013;189:1263–7
crossref pmid
15. Alvarado-Cabrero I, Sierra-Santiesteban FI, Mantilla-Morales A, Herná ndez-Hernandez DM. Micropapillary carcinoma of the urothelial tract. A clinicopathologic study of 38 cases. Ann Diagn Pathol 2005;9:1–5
crossref pmid
16. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007;110:62–7
crossref pmid
17. Kim HS, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Histological variant as the significant predictor of survival in patients with lymph node positive urothelial carcinoma of the bladder. Sci Rep 2015;5:9626
crossref pmid pmc pdf
18. Mitra AP, Bartsch CC, Bartsch G Jr, Miranda G, Skinner EC, Daneshmand S. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol 2014;32:117–27
crossref pmid
19. Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, et al. Plasmacytoid urothelial carcinoma, a che-mosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol 2013;189:1656–61
crossref pmid
20. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006;175((3 Pt 1)):881–5
crossref pmid
21. Yasui M, Morikawa T, Nakagawa T, Miyakawa J, Maeda D, Homma Y, et al. Urinary bladder carcinoma with divergent differentiation featuring small cell carcinoma, sarcomatoid carcinoma, and liposarcomatous component. Pathol Res Pract 2016;212:833–7
crossref pmid
22. Prudnick C Morley C, Shapiro R, Zaslau S. Squamous cell carcinoma of the bladder mimicking interstitial cystitis and voiding dysfunction. Case Rep Urol 2013;2013:924918
crossref pmid pmc pdf
23. Qin Q, Xu X, Wang X, Zheng XY. Obesity and risk of bladder cancer: a meta-analysis of cohort studies. Asian Pac J Cancer Prev 2013;14:3117–21
crossref pmid pdf
24. Sun JW, Zhao LG, Yang Y, Ma X, Wang YY, Xiang YB. Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PLoS One 2015;10:e0119313.
crossref pmid pmc
Editorial Office
Department of Urology, Chung-Ang University Hospital
102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-1819   Fax: +82-2-6294-1406   E-mail: journal@kjuo.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Urological Oncology Society and The Korean Prostate Society. All rights reserved.                 developed in m2community
Close layer
prev next